By ReachMD
The podcast currently has 36 episodes available.
Even though the prevalence of diabetes continues to rise globally, the good news is that there are emerging treatment options for diabetic eye diseases like nonproliferative diabetic retinopathy. Join Dr. David Brown and Dr. Rishi Singh as they review the recent evidence behind one of these options: anti-VEGF inhibitors.
Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.
Even though the prevalence of diabetes continues to rise globally, the good news is that there are emerging treatment options for diabetic eye diseases like nonproliferative diabetic retinopathy. Join Dr. David Brown and Dr. Rishi Singh as they review the recent evidence behind one of these options: anti-VEGF inhibitors.
Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.
Even though diabetic retinopathy is the leading cause of blindness among U.S. adults, a substantial number of patients with diabetes are not receiving routine eye exams and are at risk of vision loss. Making matters worse is the fact that many patients with diabetes remain unaware that this disease can affect their vision. That’s why this discussion with a panel of expert faculty will examine what it means to be proactive in promoting vision screening and minimizing the risk for vision loss with appropriate early treatment in these patients.
Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.
When it comes to protecting the vision of our patients with diabetes, the importance of taking assertive action cannot be ignored. But another key aspect that can unfortunately be easy to overlook is care collaboration. Featuring Dr. Janine Clayton, Dr. A. Paul Chous, and Dr. Anne Peters, this discussion will focus on how providers can work together to optimize patients’ eye health and minimize their risk of vision loss from diabetic retinopathy and diabetic macular edema.
Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.
As the management of diabetic retinopathy and diabetic macular edema continues to evolve, those devoted to retinal care continue to learn about what can be done now to better manage and individualize treatment for patients with these conditions. This discussion between Dr. Sharon Solomon and Dr. Charles Wykoff will review the current and emerging treatment paradigms for managing diabetic retinopathy and diabetic macular edema and considerations for applying them into clinical practice.
Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.
As the management of diabetic retinopathy and diabetic macular edema continues to evolve, those devoted to retinal care continue to learn about what can be done now to better manage and individualize treatment for patients with these conditions. This discussion between Dr. Sharon Solomon and Dr. Charles Wykoff will review the current and emerging treatment paradigms for managing diabetic retinopathy and diabetic macular edema and considerations for applying them into clinical practice.
Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.
Even though the prevalence of diabetes continues to rise globally, the good news is that there are emerging treatment options for diabetic eye diseases like nonproliferative diabetic retinopathy. Join Dr. David Brown and Dr. Rishi Singh as they review the recent evidence behind one of these options: anti-VEGF inhibitors.
Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.
When it comes to protecting the vision of our patients with diabetes, the importance of taking assertive action cannot be ignored. But another key aspect that can unfortunately be easy to overlook is care collaboration. Featuring Dr. Janine Clayton, Dr. A. Paul Chous, and Dr. Anne Peters, this discussion will focus on how providers can work together to optimize patients’ eye health and minimize their risk of vision loss from diabetic retinopathy and diabetic macular edema.
Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.
The treatment of nonproliferative diabetic retinopathy (NPDR) in the presence of diabetic macular edema is well established, but what about those patients with severe NPDR who do not have diabetic macular edema? To find out, Dr. Diana Do sits down with Dr. Peter Kaiser and Dr. Charles Wykoff, who review recent clinical trial data from the PANORAMA study and its treatment implications.
Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.
Even though diabetic retinopathy is the leading cause of blindness among U.S. adults, a substantial number of patients with diabetes are not receiving routine eye exams and are at risk of vision loss. Making matters worse is the fact that many patients with diabetes remain unaware that this disease can affect their vision. That’s why this discussion with a panel of expert faculty will examine what it means to be proactive in promoting vision screening and minimizing the risk for vision loss with appropriate early treatment in these patients.
Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.
The podcast currently has 36 episodes available.